Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04052516 · ClinicalTrials.gov registry record · Phase 2
A Phase 2b Study of Icosabutate in Fatty Liver Disease
A Phase 2 study of Non-alcoholic Steatohepatitis (NASH), sponsored by NorthSea Therapeutics B.V..
- Completed
- Registry status
- Phase 2
- Development phase
- 280
- Enrollment target
- 20
- Study locations
NCT04052516: Completed Phase 2 study of Non-alcoholic Steatohepatitis (NASH), sponsored by NorthSea Therapeutics B.V..
NCT04052516 is a Phase 2 study of Non-alcoholic Steatohepatitis (NASH) that has completed, run by NorthSea Therapeutics B.V.. The registered enrollment target is 280 participants, above the 179-participant average among 16 other Non-alcoholic Steatohepatitis (NASH) trials with a reported enrollment target (56% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04052516, a Phase 2 study of Non-alcoholic Steatohepatitis (NASH), has completed, sponsored by NorthSea Therapeutics B.V..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 280 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Phase 2b study to evaluate the efficacy of different doses of NST-4016 on the resolution of NASH without worsening of fibrosis
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Icosabutate
Study Locations (20)
California
- Fresno Clinical Research Center - Fresno
- National Research Institute - Huntington Park - Huntington Park
- National Research Institute - Wilshire - Los Angeles
- National Research Institute - Panorama - Panorama City
- Alliance Clinical Research - Poway
- National Research Institute - Santa Ana - Santa Ana
Arizona
- Arizona Liver Health - Chandler
- Arizona Liver Health - Glendale - Glendale
- Arizona Liver Health - Tucson
- Adobe Clinical Research, LLC - Tucson
Florida
- Excel Medical Clinical Trials, LLC - Boca Raton
- Sensible Healthcare LLC - Ocoee
- Covenant Research LLC - Sarasota
Louisiana
- Texas Digestive Disease Consultants - Baton Rouge
- Tandem Clinical Research - Marrero
Alabama
- Central ResearchAssociates Inc. - Birmingham
Arkansas
- Arkansas Gastroenterology - North Little Rock - North Little Rock
Colorado
- South Denver Gastroenterology - Englewood
Georgia
- Gastrointestinal Specialists of Georgia PC - Marietta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 280 participants |
| Start Date | 2019-07-17 |
| Est. Completion | 2022-12-19 |
| Phase | Phase 2 |
What the finished NCT04052516 record still lists
NCT04052516 is an interventional study that assigns participants to a tested intervention. The registered 280 participants enrollment target is mid-sized for trials with a published cap, above the 179-participant average among 16 other Non-alcoholic Steatohepatitis (NASH) trials with a reported enrollment target (56% higher).
The record links to 1 condition, with Non-alcoholic Steatohepatitis (NASH) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04052516 names 20 study sites across 9 states, led by California, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT04052516 about?
NCT04052516 is a clinical study titled "A Phase 2b Study of Icosabutate in Fatty Liver Disease". A Phase 2b study to evaluate the efficacy of different doses of NST-4016 on the resolution of NASH without worsening of fibrosis
What is the current status of trial NCT04052516?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 280 participants. The study started on 2019-07-17. Estimated completion is 2022-12-19.
What conditions does trial NCT04052516 study?
This clinical trial studies the following conditions: Non-alcoholic Steatohepatitis (NASH).
What interventions are being tested in trial NCT04052516?
The interventions under investigation include: Placebo (DRUG), Icosabutate (DRUG).
Who is sponsoring clinical trial NCT04052516?
This trial is sponsored by NorthSea Therapeutics B.V., which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04052516 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-alcoholic Steatohepatitis (NASH)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04052516's enrollment target sits among peer trials
280 3rd of 16 higher than 14 of 16 other Non-alcoholic Steatohepatitis (NASH) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-alcoholic Steatohepatitis (NASH) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy and Safety of Rencofilstat in Subjects With NASH and Advanced Liver Fibrosis
ACTIVE NOT RECRUITING · Phase 2
-
A Phase ll Study of IMM-124E for Patients With Non-alcoholic Steatohepatitis
COMPLETED · Phase 2
-
Phase 2b Study in NASH to Assess IVA337
COMPLETED · Phase 2
-
IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)
COMPLETED · Phase 2
-
Safety, Tolerability, and Efficacy of GS-4997 Alone or in Combination With Simtuzumab (SIM) in Adults With Nonalcoholic Steatohepatitis (NASH) and Fibrosis Stages F2-F3
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04084730 · 280 participants · Phase 2
Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer
- NCT04518657 · 280 participants · NA
Internet-Delivered Lifestyle Physical Activity Intervention for Cognitive Processing Speed in Multiple Sclerosis
- NCT04634916 · 280 participants · NA
Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System
- NCT04829617 · 280 participants · NA
Promoting Well-being and Health in Heart Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI